136 related articles for article (PubMed ID: 37144290)
21. Chronic fatigue in long-term survivors of Hodgkin's lymphoma after contemporary risk-adapted treatment.
Eikeland SA; Smeland KB; Simensen VC; Fagerli UM; Bersvendsen HS; Kiserud CE; Fosså A
Acta Oncol; 2023 Jan; 62(1):80-88. PubMed ID: 36715320
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
23. High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.
Park K; Yoon DH; Kim S; Park CS; Huh J; Lee SW; Suh C
Int J Hematol; 2013 Feb; 97(2):256-62. PubMed ID: 23355263
[TBL] [Abstract][Full Text] [Related]
24. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes.
Bersvendsen HS; Haugnes HS; Fagerli UM; Fluge Ø; Holte H; Smeland KB; Wilsgaard T; Kiserud CE
Acta Oncol; 2019 May; 58(5):690-699. PubMed ID: 30696346
[No Abstract] [Full Text] [Related]
25. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
[TBL] [Abstract][Full Text] [Related]
26. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
Bentolila G; Pavlovsky A
Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
[TBL] [Abstract][Full Text] [Related]
27. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Nieto Y; Thall PF; Ma J; Valdez BC; Ahmed S; Anderlini P; Popat U; Jones RB; Shpall EJ; Hosing C; Qazilbash M; Kebriaei P; Alousi A; Timmons M; Gulbis A; Myers A; Oki Y; Fanale M; Dabaja B; Pinnix C; Milgrom S; Champlin R; Andersson BS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1602-1609. PubMed ID: 29501779
[TBL] [Abstract][Full Text] [Related]
28. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
29. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Moskowitz CH; Matasar MJ; Zelenetz AD; Nimer SD; Gerecitano J; Hamlin P; Horwitz S; Moskowitz AJ; Noy A; Palomba L; Perales MA; Portlock C; Straus D; Maragulia JC; Schoder H; Yahalom J
Blood; 2012 Feb; 119(7):1665-70. PubMed ID: 22184409
[TBL] [Abstract][Full Text] [Related]
30. Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
Goodman KA; Riedel E; Serrano V; Gulati S; Moskowitz CH; Yahalom J
J Clin Oncol; 2008 Nov; 26(32):5240-7. PubMed ID: 18809615
[TBL] [Abstract][Full Text] [Related]
31. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
[TBL] [Abstract][Full Text] [Related]
32. High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.
Kondo E; Ikeda T; Izutsu K; Chihara D; Shimizu-Koresawa R; Fujii N; Sakai T; Kondo T; Kubo K; Kato Y; Akasaka T; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J; Suzuki R;
Biol Blood Marrow Transplant; 2019 May; 25(5):899-905. PubMed ID: 30664936
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
Gokmen A; Sahin U; Soydan E; Gokgoz Z; Okcu MK; Ozan U; Arslan O; Ilhan O; Ozcan M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e885-e892. PubMed ID: 35927182
[TBL] [Abstract][Full Text] [Related]
34. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Isidori A; Christofides A; Visani G
Leuk Lymphoma; 2016 Nov; 57(11):2499-509. PubMed ID: 27243412
[TBL] [Abstract][Full Text] [Related]
35. Quality of life of long-term survivors with Hodgkin lymphoma after high-dose chemotherapy, autologous stem cell transplantation, and conventional chemotherapy.
Brandt J; Dietrich S; Meissner J; Neben K; Ho AD; Witzens-Harig M
Leuk Lymphoma; 2010 Nov; 51(11):2012-20. PubMed ID: 20858092
[TBL] [Abstract][Full Text] [Related]
36. First-line high-dose therapy and autologous blood stem cell transplantation in patients with primary central nervous system non-Hodgkin lymphomas-a single-centre experience in 61 patients.
Brezina T; von Dewitz H; Schroeder T; Ullrich S; Nachtkamp K; Reifenberger G; Malzkorn B; Sabel M; Haas R; Kobbe G
Ann Hematol; 2022 Mar; 101(3):607-616. PubMed ID: 34982196
[TBL] [Abstract][Full Text] [Related]
37. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
38. Managing relapsed and refractory Hodgkin lymphoma.
Brice P
Br J Haematol; 2008 Apr; 141(1):3-13. PubMed ID: 18279457
[TBL] [Abstract][Full Text] [Related]
39. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma.
Biswas T; Culakova E; Friedberg JW; Kelly JL; Dhakal S; Liesveld J; Phillips GL; Constine LS
Radiother Oncol; 2012 Jun; 103(3):367-72. PubMed ID: 22398312
[TBL] [Abstract][Full Text] [Related]
40. Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D; Morschhauser F; Resche-Rigon M; Ghez D; Dupuis J; Marçais A; Deau-Fischer B; Bouabdallah R; Sebban C; Salles G; Brice P
Haematologica; 2016 Apr; 101(4):474-81. PubMed ID: 26721893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
